|
|
|
|
|
Last Trade
|
Last Trade:
$0.31
|
Change:
-0.0319 (-9.33%)
|
Trade Time:
May 26
|
Market Cap:
$4.81M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage, precision medicine pharmaceutical company actively
advancing a pipeline of in-licensed oncology therapeutics for patients with
difficult-to-treat cancers. Our clinical program includes three anti-cancer
assets in mid-stage clinical development and one anti-cancer asset in
early-stage clinical development. Our programs and partnerships leverage our
proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine
patient selection and improve clinical outcomes. Our DRP® technology has been
broadly validated across an extensive array of therapies and tumor types with a
high degree of accuracy for matching the right patient to the right drug.
|
|
|
|